Starling Oncology, Inc. Financials
Starling Oncology, Inc. (STLN) reported $502.7M in revenue for fiscal year 2025, up 27.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Starling Oncology, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Starling Oncology, Inc. has an operating margin of -7.2%, meaning the company loses $7 on every $100 of revenue. This results in a profitability score of 32/100. This is up from -15.3% the prior year.
Starling Oncology, Inc.'s revenue surged 27.8% year-over-year to $502.7M, reflecting rapid business expansion. This strong growth earns a score of 85/100.
Starling Oncology, Inc.'s current ratio of 1.59 indicates adequate short-term liquidity, earning a score of 44/100. The company can meet its near-term obligations, though with limited headroom.
Starling Oncology, Inc.'s operations used $24.6M of cash, and capex of $3.2M added to the outflow, for a free cash flow shortfall of $27.8M. This results in a cash flow score of 17/100.
Starling Oncology, Inc. scores 2.40, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($624.7M) relative to total liabilities ($180.4M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Starling Oncology, Inc. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Starling Oncology, Inc. reported an operating loss of $36.1M against $11.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Starling Oncology, Inc. generated $502.7M in revenue in fiscal year 2025. This represents an increase of 27.8% from the prior year.
Starling Oncology, Inc.'s EBITDA was -$29.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 45.9% from the prior year.
Starling Oncology, Inc. earned -$0.54 per diluted share (EPS) in fiscal year 2025. This represents an increase of 23.9% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Starling Oncology, Inc. recorded an outflow of $27.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 8.4% from the prior year.
Starling Oncology, Inc. held $33.6M in cash against $77.4M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Starling Oncology, Inc.'s operating margin was -7.2% in fiscal year 2025, reflecting core business profitability. This is up 8.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Starling Oncology, Inc. invested $3.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 15.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
STLN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | $587.2M | $502.7M+27.8% | $393.4M+21.3% | $324.2M+28.4% | $252.5M+24.4% | $203.0M+8.3% | $187.5M |
| SG&A Expenses | $111.4M | $105.6M-2.1% | $107.8M-5.3% | $113.9M-4.9% | $119.7M+43.6% | $83.4M+99.0% | $41.9M |
| Operating Income | -$26.1M | -$36.1M+40.0% | -$60.1M+21.9% | -$77.0M+6.0% | -$82.0M-78.7% | -$45.9M-459.4% | -$8.2M |
| Interest Expense | $7.6M | $11.3M+50.4% | $7.5M+10.6% | $6.8M+266.0% | -$4.1M-1375.6% | $320K-7.8% | $347K |
| Income Tax | $0 | -$131K | $0+100.0% | -$36K+85.2% | -$243K+63.8% | -$671K-36.1% | -$493K |
| Net Income | N/A | N/A | N/A | -$83.1M-54750.0% | $152K+101.4% | -$10.9M+23.7% | -$14.3M |
| EPS (Diluted) | — | -$0.54+23.9% | -$0.71+22.8% | -$0.92-338.1% | -$0.21-31.2% | -$0.16 | -$0.24 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
STLN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $164.7M-4.7% | $172.7M-17.5% | $209.2M-20.0% | $261.7M+28.6% | $203.4M+209.7% | $65.7M |
| Current Assets | $112.7M+0.3% | $112.4M-21.7% | $143.5M+10.0% | $130.4M-15.3% | $154.1M+418.4% | $29.7M |
| Cash & Equivalents | $33.6M-32.4% | $49.7M+48.3% | $33.5M+139.0% | $14.0M-87.8% | $115.2M+12697.1% | $900K |
| Inventory | $16.9M+68.1% | $10.0M-26.6% | $13.7M+47.7% | $9.3M+43.8% | $6.4M+47.9% | $4.4M |
| Accounts Receivable | $59.0M+22.1% | $48.3M+14.1% | $42.4M+6.4% | $39.8M+99.0% | $20.0M+16.7% | $17.1M |
| Goodwill | $7.2M0.0% | $7.2M0.0% | $7.2M-66.2% | $21.4M-19.6% | $26.6M+87.2% | $14.2M |
| Total Liabilities | $180.4M+6.7% | $169.1M+11.1% | $152.2M+9.9% | $138.5M+39.5% | $99.3M+164.1% | $37.6M |
| Current Liabilities | $71.0M+35.9% | $52.2M+50.1% | $34.8M+17.1% | $29.7M-0.3% | $29.8M+4.2% | $28.6M |
| Long-Term Debt | $77.4M-16.9% | $93.1M+7.3% | $86.8M+7.7% | $80.6M | $0-100.0% | $6.6M |
| Total Equity | -$15.7M-538.0% | $3.6M-93.7% | $57.0M-53.7% | $123.2M+18.3% | $104.2M+270.7% | $28.1M |
| Retained Earnings | -$271.4M-28.7% | -$210.8M-44.2% | -$146.2M-131.7% | -$63.1M+0.2% | -$63.2M-20.9% | -$52.3M |
STLN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $328K | -$24.6M+7.4% | -$26.5M+26.9% | -$36.3M+41.2% | -$61.8M-89.0% | -$32.7M-6533.1% | $508K |
| Capital Expenditures | $3.6M | $3.2M-15.5% | $3.8M-17.0% | $4.6M-17.4% | $5.5M+94.2% | $2.8M+138.4% | $1.2M |
| Free Cash Flow | -$3.3M | -$27.8M+8.4% | -$30.3M+25.8% | -$40.9M+39.2% | -$67.3M-89.4% | -$35.5M-5078.9% | -$686K |
| Investing Cash Flow | -$3.6M | -$3.1M-106.7% | $46.2M-26.2% | $62.6M+147.6% | -$131.6M-982.9% | -$12.2M-37.4% | -$8.8M |
| Financing Cash Flow | $14.1M | $11.6M+431.0% | -$3.5M+49.0% | -$6.8M-107.4% | $92.2M-40.1% | $154.0M+1195.5% | $11.9M |
| Share Buybacks | N/A | N/A | $0-100.0% | $1.0M-88.7% | $9.0M | $0 | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
STLN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Margin | -7.2%+8.1pp | -15.3%+8.5pp | -23.8%+8.7pp | -32.5%-9.9pp | -22.6%-18.2pp | -4.4% |
| Net Margin | N/A | N/A | -25.6%-25.7pp | 0.1%+5.4pp | -5.4%+2.3pp | -7.6% |
| Return on Equity | N/A | N/A | -145.7%-145.8pp | 0.1%+10.6pp | -10.5%+40.5pp | -51.0% |
| Return on Assets | N/A | N/A | -39.7%-39.8pp | 0.1%+5.4pp | -5.4%+16.4pp | -21.8% |
| Current Ratio | 1.59-0.6x | 2.15-2.0x | 4.12-0.3x | 4.39-0.8x | 5.17+4.1x | 1.04 |
| Debt-to-Equity | N/A | 25.95+24.4x | 1.52+0.9x | 0.65+0.7x | 0.00-0.2x | 0.23 |
| FCF Margin | -5.5%+2.2pp | -7.7%+4.9pp | -12.6%+14.0pp | -26.7%-9.2pp | -17.5%-17.1pp | -0.4% |
Not reported in any period shown, so not listed: Gross Margin.
Note: Shareholder equity is negative (-$15.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Where Starling Oncology, Inc. Ranks
Frequently Asked Questions
What is Starling Oncology, Inc.'s annual revenue?
Starling Oncology, Inc. (STLN) reported $502.7M in total revenue for fiscal year 2025. This represents a 27.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Starling Oncology, Inc.'s revenue growing?
Starling Oncology, Inc. (STLN) revenue grew by 27.8% year-over-year, from $393.4M to $502.7M in fiscal year 2025.
What is Starling Oncology, Inc.'s EBITDA?
Starling Oncology, Inc. (STLN) had EBITDA of -$29.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Starling Oncology, Inc. have?
As of fiscal year 2025, Starling Oncology, Inc. (STLN) had $33.6M in cash and equivalents against $77.4M in long-term debt.
What is Starling Oncology, Inc.'s operating margin?
Starling Oncology, Inc. (STLN) had an operating margin of -7.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Starling Oncology, Inc.'s free cash flow?
Starling Oncology, Inc. (STLN) recorded an outflow of $27.8M in free cash flow during fiscal year 2025. This represents a 8.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Starling Oncology, Inc.'s operating cash flow?
Starling Oncology, Inc. (STLN) recorded an outflow of $24.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Starling Oncology, Inc.'s total assets?
Starling Oncology, Inc. (STLN) had $164.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Starling Oncology, Inc.'s capital expenditures?
Starling Oncology, Inc. (STLN) invested $3.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Starling Oncology, Inc.'s current ratio?
Starling Oncology, Inc. (STLN) had a current ratio of 1.59 as of fiscal year 2025, which is generally considered healthy.
What is Starling Oncology, Inc.'s cash runway?
Based on fiscal year 2025 data, Starling Oncology, Inc. (STLN) had $33.6M in cash against an annual operating cash burn of $24.6M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Starling Oncology, Inc.'s debt-to-equity ratio negative or not reported?
Starling Oncology, Inc. (STLN) has negative shareholder equity of -$15.7M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Starling Oncology, Inc.'s Altman Z-Score?
Starling Oncology, Inc. (STLN) has an Altman Z-Score of 2.40, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Starling Oncology, Inc.'s Piotroski F-Score?
Starling Oncology, Inc. (STLN) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Can Starling Oncology, Inc. cover its interest payments?
Starling Oncology, Inc. (STLN) reported an operating loss of $36.1M against $11.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Starling Oncology, Inc.?
Starling Oncology, Inc. (STLN) scores 35 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.